anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
While NLRP3 contributes to kidney fibrosis, the function of most NOD-like receptors (NLRs) in chronic kidney disease (CKD) remains unexplored. To identify further NLR members involved in the pathogenesis of CKD, we searched for NLR genes expressed by normal kidneys and differentially expressed in human CKD transcriptomics databases. For NLRP6, lower kidney expression correlated with decreasing glomerular filtration rate. The role and molecular mechanisms of Nlrp6 in kidney fibrosis were explored in wild-type and Nlrp6-deficient mice and cell cultures. Data mining of single-cell transcriptomics databases identified proximal tubular cells as the main site of Nlrp6 expression in normal human kidneys and tubular cell Nlrp6 was lost in CKD. We confirmed kidney Nlrp6 downregulation following murine unilateral ureteral obstruction. Nlrp6-deficient mice had higher kidney p38 MAPK activation and more severe kidney inflammation and fibrosis. Similar results were obtained in adenine-induced kidney fibrosis. Mechanistically, profibrotic cytokines transforming growth factor beta 1 (TGF-β1) and TWEAK decreased Nlrp6 expression in cultured tubular cells, and Nlrp6 downregulation resulted in increased TGF-β1 and CTGF expression through p38 MAPK activation, as well as in downregulation of the antifibrotic factor Klotho, suggesting that loss of Nlrp6 promotes maladaptive tubular cell responses. The pattern of gene expression following Nlrp6 targeting in cultured proximal tubular cells was consistent with maladaptive transitions for proximal tubular cells described in single-cell transcriptomics datasets. In conclusion, endogenous constitutive Nlrp6 dampens sterile kidney inflammation and fibrosis. Loss of Nlrp6 expression by tubular cells may contribute to CKD progression.
Approximately 60% of all cancer diseases appear to people aged 65 years and older. Ovarian cancer is the most frequent cause of death among gynaecological malignant tumours. Since the highest carcinoma incidence is between the 60th and 70th year more women will come down with ovarian cancer because of increased life expectancy. At least 65% of patients with FIGO stage III/IV will exhibit a relapse or progress after first-line therapy. In most studies the age of the patients is limited to 65 years. It could be shown that especially elder patients often receive an inadequate operative and cytostatic therapy resulting in a worse prognosis.

Patients aged 70 years or elder who will be treated with treosulfan, given oral or intravenous, shall be compared regarding the patient compliance, toxicity especially hematological and gastrointestinal toxicity grade 3-4 (CTC NCI), overall survival, progression free survival, quality of life.
BACKGROUND: The CRC-VTE trial conducted in China revealed a significant occurrence of venous thromboembolism (VTE) in patients following colorectal cancer (CRC) surgery, raising concerns about implementing thromboprophylaxis measures. The present study aimed to identify and analyze inappropriate aspects of current thromboprophylaxis practices.
METHODS: This study performed an analysis of the CRC-VTE trial, a prospective multicenter study that enrolled 1836 patients who underwent CRC surgery. The primary objective was to identify independent risk factors for VTE after CRC surgery using multivariate logistic regression analysis. Furthermore, among the cases in which VTE occurred, the appropriateness of thromboprophylaxis was assessed based on several factors, including pharmacologic prophylaxis, time to initiate prophylaxis, drug selection, drug dosage, and duration of pharmacologic prophylaxis. Based on the analysis of the current state of thromboprophylaxis and relevant clinical guidelines, a modified Delphi method was used to develop a clinical pathway for VTE prophylaxis after CRC surgery.
RESULTS: In this analysis of 1836 patients, 205 (11.2%) were diagnosed with VTE during follow-up. The multifactorial analysis identified several independent risk factors for VTE, including age (≥70 years), female sex, varicose veins in the lower extremities, intraoperative blood transfusion, and the duration of immobilization exceeding 24 h. None of the patients diagnosed with VTE in the CRC trial received adequate thromboprophylaxis. The main reasons for this inappropriate practice were the omission of thromboprophylaxis, delayed initiation, and insufficient duration of thromboprophylaxis. We developed a specialized clinical pathway for thromboprophylaxis after CRC surgery to address these issues.
CONCLUSIONS: This study offers a comprehensive nationwide evaluation of existing thromboprophylaxis practices in patients after CRC surgery in China. A specialized clinical pathway was developed to address the identified gaps and improve the quality of care. This clinical pathway incorporates explicit, tailored, detailed recommendations for thromboprophylaxis after CRC surgery.
Novel compounds of the general formula <FORM:1035176/C2/1> wherein R1 is hydrogen, lower alkyl of 1 to 6 carbon atoms, cycloalkyl, aralkyl, substituted aralkyl, cycloalkylmethyl or acyl, R2 is lower alkyl of 1 to 6 carbon atoms, cycloalkyl, aralkyl, substituted aralkyl, phenyl or substituted phenyl, R3 is lower alkyl of 1 to 6 carbon atoms, cycloalkylmethyl, aralkyl or alkenyl and R4 is hydrogen, halogen, lower alkyl of 1 to 6 carbon atoms, lower alkoxy, nitro, amino or hydroxyl, and acid addition and quaternary ammonium salts thereof, are prepared by cyclization of a compound or a mixture of compounds of Formulae III or IV <FORM:1035176/C2/2> <FORM:1035176/C2/3> optionally followed by salt formation or quaternization of the product.  The compounds of Formulae III and IV are prepared by reduction of a compound of the Formula II: <FORM:1035176/C2/4> wherein Y is a chloride, bromide, iodide or tosylate anion.  The compounds of Formula II are prepared by quaternization of the corresponding compound of Formula I:  <FORM:1035176/C2/5> The compounds of the Formula I are prepared by reaction of a compound of the general formula <FORM:1035176/C2/6> with a phenyl hydrazine hydrochloride in acidic medium.  Compounds of the last general formula above are prepared by reaction of a compound of general formula <FORM:1035176/C2/7> with di-ethyl bromoacetal in the presence of phenyl lithium.  Therapeutic compositions in conventional form for oral or parenteral administration comprise a compound of the first general formula above and a pharmaceutically acceptable carrier therefor.  They have analgesic, anti-tussive and anti-inflammatory activity.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to derivatives of N-heteroarylpyridinesulfoneamide of the general formula (I)   where one of A 1  and A 3  means nitrogen atom and another means CH; each of A 3  and A 4  means CH; Ar means phenyl-group that may be free or carries one substituent; W, X, Y, Z can mean nitrogen atom or CH-group; R 1  is hydrogen or halogen atom, and their pharmaceutically acceptable salts. Compounds show endothelin-receptor antagonistic activity and can be useful for treatment of patients with diseases or states where increased or anomal endothelin levels have essential causative importance. Also, invention relates to methods of synthesis of compounds and their use in medicinal therapy. EFFECT: improved method of synthesis, valuable medicinal properties of compounds. 17 cl, 71 ex
OBJECTIVE: Challenging infrarenal aortic neck characteristics have been associated with an increased risk of type Ia endoleak after endovascular aneurysm repair (EVAR). Short apposition (< 10 mm circumferential shortest apposition length [SAL]) on the first post-operative computed tomography angiography (CTA) has been associated with type Ia endoleak. Therefore, this study aimed to develop a model to predict post-operative SAL in patients with an abdominal aortic aneurysm based on the pre-operative shape.
METHODS: A statistical shape model was developed to obtain principal component scores. The dataset comprised patients treated by standard EVAR without complications (n = 93) enriched with patients with a late type Ia endoleak (n = 54). The infrarenal SAL was obtained from the first post-operative CTA and subsequently binarised (< 10 mm and ≥ 10 mm). The principal component scores that were statistically different between the SAL groups were used as input for five classification models, and evaluated by means of leave one out cross validation. Area under the receiver operating characteristic curves (AUC), accuracy, sensitivity, and specificity were determined for each classification model.
RESULTS: Of the 147 patients, 24 patients had an infrarenal SAL < 10 mm and 123 patients had a SAL ≥ 10 mm. The gradient boosting model resulted in the highest AUC of 0.77. Using this model, 114 patients (77.6%) were correctly classified; sensitivity (< 10 mm apposition was correctly predicted) and specificity (≥ 10 mm apposition was correctly predicted) were 0.70 and 0.79 based on a threshold of 0.21, respectively.
CONCLUSION: A model was developed to predict which patients undergoing EVAR will achieve sufficient graft apposition (≥ 10 mm) in the infrarenal aortic neck based on a statistical shape model of pre-operative CTA data. This model can help vascular specialists during the planning phase to accurately identify patients who are unlikely to achieve sufficient apposition after standard EVAR.
Transversus abdominis plane (TAP) block is a well-described technique to provide a field block for analgesia. It has been shown to be effective in postoperative analgesia after cesarean delivery. TAP blocks are commonly performed post-operatively by anesthesiologists using liposomal bupivacaine with ultrasound guidance. Liposomal bupivacaine is an FDA approved medication for post-surgical analgesia and available at UMass-Memorial Medical Center. Liposomal bupivacaine provides sustained release of medication for up to 120 hours. A recent multicenter randomized controlled trial demonstrated the efficacy of anesthesiologist administered TAP blocks using liposomal bupivacaine after cesarean delivery. Infiltration of the skin and fascia with liposomal bupivacaine after cesarean did not have an effect and this can be explained by the path that the pain fibers take through the TAP which makes them amenable to a TAP block while a superficial infiltration is ineffective.The aim of this study is to perform a randomized trial to investigate if intraoperative surgeon administered TAP block reduces pain and use of oral and parenteral pain medications after repeat cesarean delivery. The investigators aim to compare surgeon administered TAP block with liposomal bupivacaine compared to standard treatment (i.e. no TAP block) with regard to the primary outcome of post-operative narcotic use.
Neurodegenerative diseases involve neuroinflammation and a loss of neurons, leading to disability and death. Hence, the research into new therapies has been focused on the modulation of the inflammatory response mainly by microglia/macrophages. The extracts and metabolites of marine sponges have been presented as anti-inflammatory. This study evaluated the toxicity of an extract and purified compound from the Brazilian marine sponge Aplysina fulva as well as its neuroprotection against inflammatory damage associated with the modulation of microglia response. PC12 neuronal cells and neonatal rat microglia were treated with the methanolic extract of A. fulva (AF-MeOH, 0.1-200 μg/mL) or with its purified dimethyl ketal of 3,5-dibromoverongiaquinol (AF-H1, 0.1-100 μM). Cytotoxicity was determined by MTT tetrazolium, Trypan blue, and propidium iodide; microglia were also treated with the conditioned medium (CM) from PC12 cells in different conditions. The microglia phenotype was determined by the expression of Iba-1 and CD68. AF-MeOH and AF-H1 were not toxic to PC12 or the microglia. Inflammatory damage with Escherichia coli lipopolysaccharide (LPS, 5 μg/mL) was not observed in the PC12 cells treated with AF-MeOH (1-10 μg/mL) or AF-H1 (1-10 μM). Microglia subjected to the CM from PC12 cells treated with LPS and AF-MeOH or AF-H1 showed the control phenotype-like (multipolar, low-CD68), highlighting the anti-neuroinflammatory and neuroprotective effect of components of this marine sponge.
INTRODUCTION: to help reduce neonatal mortality in Burkina Faso, we identified the prognostic factors for neonatal mortality at the Sourô Sanou University Hospital.
METHODS: we conducted a cross-sectional and analytical study in the neonatal department from July 25, 2019 to June 25, 2020. Patients' medical records, consultation and hospital records were reviewed. Prognostic factors for neonatal mortality were identified using a Cox model.
RESULTS: data from 1128 newborn babies were analysed. Neonatal mortality was 29.8%. Most of these deaths (89%) occurred in the early neonatal period. The mean weight of newborns at the admission was 2,285.8 ± 878.7 and 43.6%. They were at a healthy weight. Four out of five newborns had been hospitalized for infection or prematurity. The place of delivery (HR weight <1000g = 5.45[3.81 -7.79]) and the principal diagnosis (HR asphyxiation= 1.64[1.30-2.08]) were prognostic factors for neonatal mortality.
CONCLUSION: improving technical facilities for the etiological investigation of infections and an efficient management of low-weight newborns suffering from respiratory distress would considerably reduce in-hospital neonatal mortality in Bobo-Dioulasso.
<P>PROBLEM TO BE SOLVED: To provide a new anti-obesity agent eliminating life style related diseases caused by obesity such as cardiovascular diseases, type 2 diabetes and cancer.  <P>SOLUTION: The anti-obesity agent is obtained by using curcumin. A crude drug having enhancing actions on immune strength is used in combination. A crude drug having hydragogue actions is used in combination. Isoflavone or an isoflavone glycoside is used combination. The blood level of curcumin is maintained at 0.5-100 μM.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PURPOSE:To obtain a pressure sensitive tacky agent consisting essentially of a rubber based tacky agent, tackifying resin having a polar group and softening agent and capable of carrying out control of releasing property and retaining property of nitroglycerin. CONSTITUTION:The aimed tape or sheet containing (A) a rubber based tacky agent base selected from a diene based rubber containing a natural rubber, isoprene based rubber, isobutylene based rubber and styrene as copolymer components, (B) at least one kind or polar substance selected from the group consisting of B1: tackifier (e.g. rosin ester based resin) and B2: softening agent (e.g. lanolin derivative) and as necessary (C) at least one kind of non-polar substance having no polar group and selected from the group consisting of C1: tackifying resin (e.g. poly-beta-pinene resin) and softening agent (e.g. vaseline). These components are normally blended at amounts of the component B1 of 20-120 pts.wt. component C1 of 0-120 pts.wt. component B2 of 0-50 pts.wt. and component C2 of 0-50 pts.wt. based on the component A of 100 pts.wt.
PROBLEM TO BE SOLVED: To provide a composition containing ibudilast stabilized at a high level even in an aqueous solution. SOLUTION: The stability of the ibudilast to the light is improved by adding 0.01-100,000 pts.wt. xanthines (caffeine, theophylline or the like) based on 1 pts.wt. ibudilast. The composition is useful as an aqueous composition, e.g. a topically applied composition such as an eye drop, and a composition applied to the mucous membrane.
This class of compounds is known to complex cations such as calcium. Particular caution should be used with patients who have, or may be predisposed to hypocalcemia (i.e., alkalosis).

Preliminary reports indicate impairment of brain scans using Sodium Pertechnetate Tc 99m Injection which have been preceded by a bone scan using an agent containing stannous ions. The impairment may result in false-positive or false-negative brain scans. It is recommended, where feasible, that brain scans precede bone imaging procedures. Alternatively, a brain imaging agent such as Technetium Tc 99m Pentetate Injection may be employed.
The investigators have previously used a high-sodium saline infusion to increase blood sodium and consequently increase blood pressure in Black and White individuals. The investigators' prior data suggest that increased blood sodium concentrations result in larger blood pressure elevations for a given elevation in blood sodium levels in Black compared to White adults. In this proposal, the investigators are seeking to translate these previous findings using a single high-salt meal (up to 2500 mg of sodium; similar to a few slices of pizza or a sandwich/burger and side dish). Our primary aims are to determine if the high-sodium meal causes greater 1) blood pressure dysregulation 2) decreases in blood vessel function and 3) larger changes in blood sodium in Black compared to White individuals. Other potential questions that could be determined include aging differences or an influence of fitness. The investigators will not exclude other races/ethnicities as the project will also determine the response of other minority groups (e.g. Asian or Latine/Hispanic adults) to a high-salt meal.
The invention relates to a method for processing neurosis capsules having a formula of medical materials comprising pilose asiabell root, feihuoshi, chrysanthemum, etc. By using a dreg-removing and concentrating manufacture method, radix rehmanniae and aged wine, in a ratio of 1:2.5 by kilogram, are boiled together with a small amount of vinegar, and then dregs are removed and juice is taken to reserve. Medical materials of plantain, Sichuan-produced coptis and honeysuckle are boiled in water after being smashed, and then dregs are removed and juice is taken to reserve. Medical materials of monochoria vaginalis, chrysanthemum and cortex moutan are soaked in water for half an hour, and then boiled and juice is taken to reserve. The three kinds of reserved juice are mixed and then together with unused medical materials in the formula, are stirred, dried in the sun and grinded in all to obtain powder. The powder is sifted over a 180 mesh sieve and then made into capsules. Four to five capsules can be taken at every time, twice per day, and a treatment course is 100 days. When the capsules are taken for a month, symptoms of insomnia, red leucorrhoea, cystitis, etc., are improved obviously. When the capsules are taken throughout the treatment course, neurosis and anemia can be treated forever and a plurality of gynecologic diseases can be recuperated at the same time. Effects of skin whitening, beauty improving, and skin softening can be also achieved.
OBJECTIVES: Sleep disorders are frequently encountered non-motor symptoms that significantly impact the lifestyle quality of individuals with Parkinson's disease (PD). Our research endeavors to research the sleep quality of PD patients and define the occurrence of excessive daytime sleepiness (EDS) and nocturnal difficulties within this population.
METHODS: We incorporated 140 patients diagnosed with PD and 75 healthy individuals as controls. The modified Hoehn & Yahr Staging Scale (HYS) was employed for the clinical classification of PD stages, while the evaluation of clinical intensity utilized the Unified Parkinson's Disease Rating Scale (UPDRS). The assessment of sleep quality utilized the Pittsburgh Sleep Quality Index (PSQI), along with the Parkinson's Disease Sleep Scale (PDSS), and the Epworth Sleepiness Scale (ESS). Additionally, the subjective depression levels of attendees were assessed by the Beck Depression Inventory.
RESULTS: In contrast to the healthy controls, the patient cohort demonstrated notably higher scores across the PSQI scale, ESS, and Beck Depression Scale (p < 0.05). Within the PD patient group, 66.4% exhibited poor sleep quality, and 17.1% reported excessive daytime sleepiness. A significant positive correlation was between poor sleep quality and factors such as H&Y stage, duration of levodopa exposure, scores on the ESS, and the BDI (p < 0.05). Additionally, EDS was positively correlated with UPDRS-I scores, Levodopa equivalent daily dose, PSQI, and BDI scores (p < 0.05).
DISCUSSION: Addressing the specific etiology of sleep disorders in Parkinson's patients has the potential to result in improved treatment outcomes and enhanced functionality in their daily lives.
Celiac disease (CD) is an autoimmune enteropathy resulting from an interaction between diet, genome, and immunity. Although many patients respond to a gluten-free diet, in a substantive number of individuals, the intestinal injury persists. Thus, other factors might amplify the ongoing inflammation. Candida albicans is a commensal fungus that is well adapted to the intestinal life. However, specific conditions increase Candida pathogenicity. The hypothesis that Candida may be a trigger in CD has been proposed after the observation of similarity between a fungal wall component and two CD-related gliadin T-cell epitopes. However, despite being implicated in intestinal disorders, Candida may also protect against immune pathologies highlighting a more intriguing role in the gut. Herein, we postulated that a state of chronic inflammation associated with microbial dysbiosis and leaky gut are favorable conditions that promote C. albicans pathogenicity eventually contributing to CD pathology via a mast cells (MC)-IL-9 axis. However, the restoration of immune and microbial homeostasis promotes a beneficial C. albicans-MC cross-talk favoring the attenuation of CD pathology to alleviate CD pathology and symptoms.
<P>PROBLEM TO BE SOLVED: To obtain liquid crystal gel composed of curdlan in which curdlan molecule itself has gelation function and liquid crystal formation function and which does not cause harm to the human body and has biodegradability and an optical gradient of double refractive index.  <P>SOLUTION: The liquid crystal gel composed of curdlan is formed in a filamentous, cylindrical or spherical shape. In the case of filamentous and cylindrical shapes, when the liquid crystal gel is observed in a cross section perpendicular to the length direction and in the case of spherical shape, when the liquid crystal gel is observed in the direction of diameter, the liquid crystal gel is oriented radially from the center, respectively and has a concentric circler multilayer structure. The cylindrical liquid crystal gel is produced by dissolving 0.5-12 parts wt. of curdlan in an alkali aqueous solution having an alkali concentration of 0.05-2 normalities at 40°C to give a stock solution, packing and sealing the stock solution in a dialysis membrane tube, immersing the tube in an aqueous solution containing a calcium salt having a calcium concentration of 0.02-7.2 normalities at ≤45°C to dialyze the stock solution.  <P>COPYRIGHT: (C)2006,JPO&NCIPI